HOME >> MEDICINE >> NEWS
Emory University researchers find clue to Huntington's disease mechanism

ATLANTA- Huntington's disease, an inherited progressive neurological disorder, often results in the degeneration of neurons in the hypothalamus, a part of the brain that controls appetite and body weight. Scientists at Emory University School of Medicine have discovered how rogue proteins generated by the genetic mistake present in Huntington's disease poison neurons in the hypothalamus. They demonstrate that the mutant proteins interfere with the function of another protein abundant in the hypothalamus huntingtin-associated protein-1 (HAP1).

The research is published in the July 30 issue of the Journal of Neuroscience. Lead authors are Shi-Hua Li, MD and Xiao-Jiang Li, PhD, faculty members in Emory's Department of Human Genetics, and Zhao-Xue Yu, PhD, postdoctoral fellow. Dr. Chuxia Deng's laboratory at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) also contributed to the study.

Huntington's disease eventually affects many parts of the brain, but the strongest impact is on the basal ganglia, responsible for coordination of movement. Onset usually occurs between 30 and 50 years of age, and the symptoms become progressively worse over the next 15 years. The main symptoms include loss of control of movement, depression and cognitive impairment. Complications include loss of body weight, heart failure and pneumonia. Huntington's occurs at a frequency of five to seven in a hundred thousand, and some relatives of affected individuals have a 50 percent risk of inheriting the responsible mutation responsible. No effective treatment exists.

Huntington's patients suffer from the genetic equivalent of a skipping record or CD In the gene responsible the huntingtin gene the enzymes that copy genetic information get stuck and make additional repeats of the same three-letter sequence CAG. When the number of repeats grows large enough, the property and function of the protein change. The now-expanded region of the pro
'"/>

Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory University Health Sciences Center
31-Jul-2003


Page: 1 2 3

Related medicine news :

1. Emory Study finds HIV is not an independent risk factor for severe heart disease
2. Emory cardiologists present research at AHA scientific sessions in New Orleans, Nov. 7 - 10
3. Emory study finds mental health and heart disease tightly linked
4. Emory conference to educate health professionals about metabolic syndrome
5. Emory researcher examines effects of antiepileptic drugs on pregnant women and their offspring
6. Emory researchers find race and gender gaps in treatment of heart attack
7. Emory, GlaxoSmithKline, NIMH enter public-private partnership to develop new drugs for depression
8. Emory and CDC scientists explore why most breastfed infants of HIV-positive mothers resist infection
9. Emory scientists find marker for long-term immunity
10. Emory scientists find oral tetrahydrobiopterin can reduce high blood pressure
11. Emory scientists link atrial fibrillation with decrease in nitrous oxide

Post Your Comments:
(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... a study published today in PLOS Pathogens , ... malaria is common can mount an immune response to ... avoid repeated bouts of high fever and illness and ... bloodstream. The findings may help researchers develop future interventions ... malaria parasite. , Each year, approximately 200 million cases ...
(Date:4/17/2014)... In a review published in the April issue of ... The Feinstein Institute for Medical Research, says it,s time ... approach to treating sepsis, which kills millions ... Sepsis occurs when molecules released into the bloodstream to ... body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... revenues for the fourth quarter of 2013 will be ... approximately $208 million. "Our full-year revenue growth ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: